163 related articles for article (PubMed ID: 11821750)
1. Effects of lansoprazole and rabeprazole on tacrolimus blood concentration: case of a renal transplant recipient with CYP2C19 gene mutation.
Homma M; Itagaki F; Yuzawa K; Fukao K; Kohda Y
Transplantation; 2002 Jan; 73(2):303-4. PubMed ID: 11821750
[No Abstract] [Full Text] [Related]
2. Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations.
Itagaki F; Homma M; Yuzawa K; Nishimura M; Naito S; Ueda N; Ohkohchi N; Kohda Y
J Pharm Pharmacol; 2004 Aug; 56(8):1055-9. PubMed ID: 15285851
[TBL] [Abstract][Full Text] [Related]
3. Drug interaction of tacrolimus and proton pump inhibitors in renal transplant recipients with CYP2C19 gene mutation.
Itagaki F; Homma M; Yuzawa K; Fukao K; Kohda Y
Transplant Proc; 2002 Nov; 34(7):2777-8. PubMed ID: 12431607
[No Abstract] [Full Text] [Related]
4. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole.
Adachi K; Katsube T; Kawamura A; Takashima T; Yuki M; Amano K; Ishihara S; Fukuda R; Watanabe M; Kinoshita Y
Aliment Pharmacol Ther; 2000 Oct; 14(10):1259-66. PubMed ID: 11012469
[TBL] [Abstract][Full Text] [Related]
5. Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients.
Miura M; Inoue K; Kagaya H; Satoh S; Tada H; Sagae Y; Habuchi T; Suzuki T
Biopharm Drug Dispos; 2007 May; 28(4):167-75. PubMed ID: 17377957
[TBL] [Abstract][Full Text] [Related]
6. [Cause and prevention of nocturnal gastric acid breakthrough].
Adachi K; Kinoshita Y
Nihon Rinsho; 2002 Feb; 60 Suppl 2():779-83. PubMed ID: 11979888
[No Abstract] [Full Text] [Related]
7. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs.
Meyer UA
Eur J Gastroenterol Hepatol; 1996 Oct; 8 Suppl 1():S21-5. PubMed ID: 8930576
[TBL] [Abstract][Full Text] [Related]
8. Distinct effects of omeprazole and rabeprazole on the tacrolimus blood concentration in a kidney transplant recipient.
Takahashi K; Yano I; Fukuhara Y; Katsura T; Takahashi T; Ito N; Yamamoto S; Ogawa O; Inui K
Drug Metab Pharmacokinet; 2007 Dec; 22(6):441-4. PubMed ID: 18159131
[TBL] [Abstract][Full Text] [Related]
9. CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects.
Sakai T; Aoyama N; Kita T; Sakaeda T; Nishiguchi K; Nishitora Y; Hohda T; Sirasaka D; Tamura T; Tanigawara Y; Kasuga M; Okumura K
Pharm Res; 2001 Jun; 18(6):721-7. PubMed ID: 11474773
[TBL] [Abstract][Full Text] [Related]
10. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers.
Saitoh T; Fukushima Y; Otsuka H; Hirakawa J; Mori H; Asano T; Ishikawa T; Katsube T; Ogawa K; Ohkawa S
Aliment Pharmacol Ther; 2002 Oct; 16(10):1811-7. PubMed ID: 12269976
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism.
Ieiri I; Kishimoto Y; Okochi H; Momiyama K; Morita T; Kitano M; Morisawa T; Fukushima Y; Nakagawa K; Hasegawa J; Otsubo K; Ishizaki T
Eur J Clin Pharmacol; 2001 Sep; 57(6-7):485-92. PubMed ID: 11699613
[TBL] [Abstract][Full Text] [Related]
12. [Recent topics on important drugs for H. pylori eradication: Rabeprazole].
Sugimoto M; Furuta T; Nakmura A; Shirai N
Nihon Rinsho; 2005 Nov; 63 Suppl 11():350-3. PubMed ID: 16363558
[No Abstract] [Full Text] [Related]
13. Lansoprazole-tacrolimus interaction in Japanese transplant recipient with CYP2C19 polymorphism.
Takahashi K; Motohashi H; Yonezawa A; Okuda M; Ito N; Yamamoto S; Ogawa O; Inui K
Ann Pharmacother; 2004 May; 38(5):791-4. PubMed ID: 15010519
[TBL] [Abstract][Full Text] [Related]
14. Rabeprazole experience in Korea; focus on CYP2C19 polymorphism.
Park SH
J Gastroenterol Hepatol; 2005 Dec; 20 Suppl():S20-1. PubMed ID: 16359345
[No Abstract] [Full Text] [Related]
15. Different contribution of CYP2C19 in the in vitro metabolism of three proton pump inhibitors.
Kita T; Sakaeda T; Baba T; Aoyama N; Kakumoto M; Kurimoto Y; Kawahara Y; Okamura N; Kirita S; Kasuga M; Okumura K
Biol Pharm Bull; 2003 Mar; 26(3):386-90. PubMed ID: 12612455
[TBL] [Abstract][Full Text] [Related]
16. [High dose dual PPI/AMPC therapy for the treatment of Helicobacter pylori infection after failure of usual standard triple PPI/AMPC/CAM therapy: CYP2C19 polymorphism].
Shirai N; Furuta T
Nihon Rinsho; 2002 Feb; 60 Suppl 2():439-44. PubMed ID: 11979823
[No Abstract] [Full Text] [Related]
17. Enantioselective disposition of lansoprazole and rabeprazole in human plasma.
Miura M
Yakugaku Zasshi; 2006 Jun; 126(6):395-402. PubMed ID: 16755125
[TBL] [Abstract][Full Text] [Related]
18. Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19.
Shimatani T; Inoue M; Kuroiwa T; Xu J; Mieno H; Nakamura M; Tazuma S
Clin Pharmacol Ther; 2006 Jan; 79(1):144-52. PubMed ID: 16413249
[TBL] [Abstract][Full Text] [Related]
19. Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers.
Miura M; Kagaya H; Tada H; Sagae Y; Satoh S; Habuchi T; Suzuki T
Xenobiotica; 2005 May; 35(5):479-86. PubMed ID: 16012079
[TBL] [Abstract][Full Text] [Related]
20. Acid-suppressive efficacy of a reduced dosage of rabeprazole: comparison of 10 mg twice daily rabeprazole with 20 mg twice daily rabeprazole, 30 mg twice daily lansoprazole, and 20 mg twice daily omeprazole by 24-hr intragastric pH-metry.
Shimatani T; Inoue M; Kuroiwa T; Xu J; Tazuma S; Horikawa Y; Nakamura M
Dig Dis Sci; 2005 Jul; 50(7):1202-6. PubMed ID: 16047460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
